Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kazia Therapeutics ( (KZIA) ) just unveiled an announcement.
On September 11, 2025, Kazia Therapeutics announced significant findings from a study on paxalisib, its investigational PI3K–mTOR inhibitor, which showed complete disruption of circulating tumor cell clusters in Stage IV HER2-positive metastatic breast cancer. This breakthrough highlights paxalisib’s potential to address aggressive disease and metastasis, offering a new therapeutic avenue for patients with limited options. The study complements Kazia’s ongoing trials in other breast cancer subtypes, reinforcing the broader applicability of paxalisib in oncology.
The most recent analyst rating on (KZIA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.
Spark’s Take on KZIA Stock
According to Spark, TipRanks’ AI Analyst, KZIA is a Underperform.
Kazia Therapeutics has a low overall stock score due to significant financial instability marked by declining revenues, negative equity, and cash flow issues. Technical indicators suggest bearish momentum, and poor valuation metrics reflect the company’s unprofitability. The absence of dividends and positive earnings call or corporate events data further emphasize the company’s challenges.
To see Spark’s full report on KZIA stock, click here.
More about Kazia Therapeutics
Kazia Therapeutics Limited, based in Sydney, Australia, is an oncology-focused drug development company. Its lead program, paxalisib, is an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, developed to treat multiple forms of cancer. The company is also developing EVT801, a small molecule inhibitor of VEGFR3, licensed from Evotec SE.
Average Trading Volume: 274,706
Technical Sentiment Signal: Sell
Current Market Cap: $9.22M
For detailed information about KZIA stock, go to TipRanks’ Stock Analysis page.